Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
dc.contributor.author | Simpson-Yap, S | en_US |
dc.contributor.author | Pirmani, A | en_US |
dc.contributor.author | Kalincik, T | en_US |
dc.contributor.author | De Brouwer, E | en_US |
dc.contributor.author | Geys, L | en_US |
dc.contributor.author | Parciak, T | en_US |
dc.contributor.author | Helme, A | en_US |
dc.contributor.author | Rijke, N | en_US |
dc.contributor.author | Hillert, JA | en_US |
dc.contributor.author | Moreau, Y | en_US |
dc.contributor.author | Edan, G | en_US |
dc.contributor.author | Sharmin, S | en_US |
dc.contributor.author | Spelman, T | en_US |
dc.contributor.author | McBurney, R | en_US |
dc.contributor.author | Schmidt, H | en_US |
dc.contributor.author | Bergmann, AB | en_US |
dc.contributor.author | Braune, S | en_US |
dc.contributor.author | Stahmann, A | en_US |
dc.contributor.author | Middleton, RM | en_US |
dc.contributor.author | Salter, A | en_US |
dc.contributor.author | Bebo, B | en_US |
dc.contributor.author | Van der Walt, A | en_US |
dc.contributor.author | Butzkueven, H | en_US |
dc.contributor.author | Ozakbas, S | en_US |
dc.contributor.author | Boz, C | en_US |
dc.contributor.author | Karabudak, R | en_US |
dc.contributor.author | Alroughani, R | en_US |
dc.contributor.author | Rojas, JI | en_US |
dc.contributor.author | van der Mei, IA | en_US |
dc.contributor.author | Sciascia do Olival, G | en_US |
dc.contributor.author | Magyari, M | en_US |
dc.contributor.author | Alonso, RN | en_US |
dc.contributor.author | Nicholas, RS | en_US |
dc.contributor.author | Chertcoff, AS | en_US |
dc.contributor.author | de Torres, AZ | en_US |
dc.contributor.author | Arrambide, G | en_US |
dc.contributor.author | Nag, N | en_US |
dc.contributor.author | Descamps, A | en_US |
dc.contributor.author | Costers, L | en_US |
dc.contributor.author | Dobson, R | en_US |
dc.contributor.author | Miller, A | en_US |
dc.contributor.author | Rodrigues, P | en_US |
dc.contributor.author | Prčkovska, V | en_US |
dc.contributor.author | Comi, G | en_US |
dc.contributor.author | Peeters, LM | en_US |
dc.date.accessioned | 2022-09-15T10:39:13Z | |
dc.date.available | 2022-07-27 | en_US |
dc.date.issued | 2022-11 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/80533 | |
dc.description.abstract | BACKGROUND AND OBJECTIVES: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. METHODS: Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. RESULTS: Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1-7] and 7% [95% CI 4-11]), ICU/artificial ventilation (2% [95% CI 0-4] and 4% [95% CI 2-6]), and death (1% [95% CI 0-2] and 2% [95% CI 1-4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2-8), 3% (95% CI 1-5), and 1% (95% CI 0-3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. DISCUSSION: Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Neurol Neuroimmunol Neuroinflamm | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | Antigens, CD20 | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Glatiramer Acetate | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunosuppressive Agents | en_US |
dc.subject | Information Dissemination | en_US |
dc.subject | Male | en_US |
dc.subject | Multiple Sclerosis | en_US |
dc.subject | Multiple Sclerosis, Chronic Progressive | en_US |
dc.subject | Natalizumab | en_US |
dc.subject | Risk Factors | en_US |
dc.subject | Rituximab | en_US |
dc.title | Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1212/NXI.0000000000200021 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36038263 | en_US |
pubs.issue | 6 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 9 | en_US |
dcterms.dateAccepted | 2022-07-27 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Centre for Cancer Prevention [1179]